"Carbamates" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Derivatives of carbamic acid, H2NC(=O)OH. Included under this heading are N-substituted and O-substituted carbamic acids. In general carbamate esters are referred to as urethanes, and polymers that include repeating units of carbamate are referred to as POLYURETHANES. Note however that polyurethanes are derived from the polymerization of ISOCYANATES and the singular term URETHANE refers to the ethyl ester of carbamic acid.
| Descriptor ID |
D002219
|
| MeSH Number(s) |
D02.241.081.251
|
| Concept/Terms |
Carbamic Acids- Carbamic Acids
- Acids, Carbamic
- Aminoformic Acids
- Acids, Aminoformic
|
Below are MeSH descriptors whose meaning is more general than "Carbamates".
Below are MeSH descriptors whose meaning is more specific than "Carbamates".
This graph shows the total number of publications written about "Carbamates" by people in this website by year, and whether "Carbamates" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2014 | 2 | 1 | 3 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2020 | 0 | 2 | 2 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carbamates" by people in Profiles.
-
Pharmacological Advantage of SIRT2-Selective versus pan-SIRT1-3 Inhibitors. ACS Chem Biol. 2021 07 16; 16(7):1266-1275.
-
Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/- binimetinib or alpelisib. Br J Cancer. 2021 01; 124(1):176-182.
-
A DNA-based fluorescent probe maps NOS3 activity with subcellular spatial resolution. Nat Chem Biol. 2020 06; 16(6):660-666.
-
Monoacylglycerol Lipase Inhibitors Reverse Paclitaxel-Induced Nociceptive Behavior and Proinflammatory Markers in a Mouse Model of Chemotherapy-Induced Neuropathy. J Pharmacol Exp Ther. 2018 07; 366(1):169-183.
-
A Fluorescent Probe with Improved Water Solubility Permits the Analysis of Protein S-Depalmitoylation Activity in Live Cells. Biochemistry. 2018 01 16; 57(2):221-225.
-
Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis. Clin Gastroenterol Hepatol. 2017 03; 15(3):421-430.e6.
-
Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. Lancet Gastroenterol Hepatol. 2016 10; 1(2):122-132.
-
Sofosbuvir and Velpatasvir for Patients with HCV Infection. N Engl J Med. 2016 04 28; 374(17):1688.
-
Retigabine holds KV7 channels open and stabilizes the resting potential. J Gen Physiol. 2016 Mar; 147(3):229-41.
-
Synthesis, biological studies and molecular dynamics of new anticancer RGD-based peptide conjugates for targeted drug delivery. Bioorg Med Chem. 2016 Jan 15; 24(2):294-303.